You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
東誠藥業(002675.SZ)擬投資 APRINOIA Therapeutics Inc. 持股預計16%
格隆匯 02-05 19:30

格隆匯2月5日丨東誠藥業(002675.SZ)公佈,2021年2月5日,公司與APRINOIA Therapeutics Inc.(以下簡稱“目標公司”)簽署了《C系列優先股認購協議》,以現金1807.29萬美元認購目標公司增發的1348.72萬股C系列優先股,佔此次增發股份的86%;同時在本輪投資交割前,按照公司可接受的條件購買其原有股東部分股權,數量不低於385.43萬股。本輪投資和員工期權發放完成後,預計公司在目標公司的持股比例為16%。

目標公司專注於阿爾茨海默症、帕金森症等神經退行性疾病的放射性核素診斷與治療藥品的研發,其中18F-APN-1607目前在國內處於三期臨牀階段。公司致力於在全國佈局放射性藥物運營平台,本次對於目標公司的投資有利於公司完善放射性藥物平台的產品線,增加公司在核素藥物研發、生產、配送等方面的協同效應,降低未來核藥生產基地的單位運營成本,增強公司產品的核心競爭力,符合公司的核醫藥產業佈局與發展戰略。同時,介於目標公司的產品均處於研發階段,存在研發失敗而給公司帶來投資損失的不確定性。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account